PharmaCyte Biotech, Inc. (PMCB) Institutional Ownership

Ownership Summary

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) has 28 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors held 14.5% of outstanding shares in December 2025, up from 6.4% in September 2025.
• They increased total shares held in PharmaCyte Biotech by 126.83% from the prior quarter, while the number of investors in PMCB increased 33.33% year over year.
• Of these 28 funds, 12 grew their exposure to PharmaCyte Biotech, 8 cut back, and 8 maintained positions.
• The aggregate institutional position in PharmaCyte Biotech amounted to 984.12K shares as of December 2025, up by 550.27K shares quarter on quarter, and up 382.85K shares year over year.
• CITADEL ADVISORS LLC is the top holder of PharmaCyte Biotech as of December 31, 2025, with 229.72K shares representing 3.38% of outstanding stock.
• The biggest buyers of PharmaCyte Biotech for the quarter ending December 2025 included CITADEL ADVISORS LLC (215.19K), HRT FINANCIAL LP (182.8K), SABBY MANAGEMENT, LLC (100.0K), SIMPLEX TRADING, LLC (24.73K), TWO SIGMA SECURITIES, LLC (24.55K).
• The largest sellers of PharmaCyte Biotech for the quarter ending December 2025 were EQUITEC PROPRIETARY MARKETS, LLC (60.5K), GEODE CAPITAL MANAGEMENT, LLC (2.76K), Bank Of America Corp /De/ (762), Tower Research Capital LLC (TRC) (653), Schonfeld Strategic Advisors LLC (22).
• PharmaCyte Biotech's 10 largest shareholders as of December 2025 include CITADEL ADVISORS LLC (229.72K), HRT FINANCIAL LP (182.8K), GEODE CAPITAL MANAGEMENT, LLC (123.84K), SABBY MANAGEMENT, LLC (100.0K), RENAISSANCE TECHNOLOGIES LLC (94.04K), VANGUARD GROUP INC (74.92K), Northern Trust Corp (35.6K), Schonfeld Strategic Advisors LLC (26.18K), SIMPLEX TRADING, LLC (25.83K), TWO SIGMA SECURITIES, LLC (24.55K) per Business Quant data.